Randomized Controlled Trial for Paclitaxel-coated Balloon versus Plain Balloon Angioplasty in Dysfunctional Hemodialysis Vascular Access: 12-month Outcome from a Nonsponsored Trial

医学 气球 血管成形术 切割气球 血液透析 外科 随机对照试验 失调家庭 紫杉醇 血管通路 内科学 支架 化疗 再狭窄 精神科
作者
Skyi Yin-Chun Pang,Karen C.L. Au-Yeung,Grace Y.L. Liu,Ronald On‐Ho Tse,Donna Lai,Warren K W Leung,Ka Leung Mo,Chung Ngai Tang,Patricia Chun‐Ling Yih
出处
期刊:Annals of Vascular Surgery [Elsevier BV]
卷期号:72: 299-306 被引量:14
标识
DOI:10.1016/j.avsg.2020.10.005
摘要

Plain balloon angioplasty is regarded as the mainstay of treatment for failing vascular access with high success rate, but the poor treatment durability creates significant workload and increases patient morbidity. The study aims to compare target lesion primary patency rate at 12 months between paclitaxel-coated balloon (DCB) versus plain old balloon angioplasty (POBA) for treatment of dysfunctional vascular access.This nonsponsored-randomized trial enrolled 40 patients with dysfunctional dialysis access at a single center. Patients were randomized into In.Pact Admiral Paclitaxel DCB or POBA after lesion crossing regardless of lesion type. Patients are followed up under surveillance protocol. Patients, hemodialysis staff, and sonographer are blinded to the treatment arms. Twelve-month primary patency rate in both arms are evaluated.40 patients were recruited since June 2016 and were allocated to the DCB or POBA group. The mean age is 58 and 57 years with comparable demographic parameters. The locations of target lesion were comparable in both groups (juxta and arteriovenous anastomosis, cannulation site, and fistula/graft), with similar mean target lesion stenosis 69.8 +/- 15.8% for DCB and 69.5 +/- 13.6% for POBA (P = 0.95), and the lesion length for DCB is 45.8 +/- 38.4 mm and 50.2 +/- 33.5 mm for POBA (P = 0.70). Patients in DCB performed significantly better in terms of primary patency at 6 months 85% versus 55% (P = 0.007). The superiority in primary patency in DCB group exists at 12 months 65% versus 30% (P = 0.007).Paclitaxel balloon angioplasty approach provides significant better primary patency in dysfunctional arteriovenous access at 12 months in our nonsponsored-randomized trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
2秒前
玥越完成签到,获得积分10
2秒前
dm11完成签到 ,获得积分10
3秒前
Akim应助靖123456采纳,获得10
4秒前
yizhe完成签到,获得积分10
4秒前
畅畅完成签到 ,获得积分10
4秒前
ChatGPT发布了新的文献求助10
5秒前
李健的小迷弟应助la采纳,获得10
5秒前
ZYN完成签到 ,获得积分10
6秒前
Mason完成签到,获得积分10
7秒前
yizhe发布了新的文献求助10
7秒前
JamesPei应助zzzz采纳,获得10
8秒前
英俊的铭应助aa采纳,获得30
8秒前
xiaohuhuan完成签到,获得积分10
8秒前
bulingbuling完成签到 ,获得积分10
9秒前
一颗小纽扣完成签到,获得积分10
10秒前
席涑完成签到,获得积分10
11秒前
CipherSage应助拼搏的婷冉采纳,获得10
11秒前
luoluo完成签到 ,获得积分10
12秒前
12秒前
醋炒栗子仁完成签到,获得积分10
12秒前
墨尔根戴青完成签到,获得积分10
13秒前
瑾瑜完成签到,获得积分10
14秒前
文小杰完成签到,获得积分10
14秒前
山月完成签到,获得积分10
15秒前
CodeCraft应助研友_LOK59L采纳,获得10
15秒前
15秒前
16秒前
欣慰妙海完成签到 ,获得积分20
16秒前
CodeCraft应助zhaopeipei采纳,获得10
16秒前
LIUYONG发布了新的文献求助10
17秒前
lin发布了新的文献求助10
19秒前
20秒前
九湖夷上完成签到 ,获得积分10
20秒前
噼里啪啦完成签到 ,获得积分10
21秒前
大个应助hahaha123213123采纳,获得30
21秒前
21秒前
惊天大幂幂完成签到,获得积分10
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029